540 related articles for article (PubMed ID: 34517987)
1. Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID study.
Trias F; Pintó X; Corbella E; Suárez-Tembra M; Ruíz-García A; Díaz-Díaz JL; Sánchez-Ruíz-Granado E; Sarasa I; Martínez-Porqueras R; Rodríguez-Sánchez MA; Corbella X;
Med Clin (Barc); 2022 Jun; 158(11):531-539. PubMed ID: 34517987
[TBL] [Abstract][Full Text] [Related]
2. Do Statins Counteract the Effect of Antidiabetic Drugs? Results of the SCEAD Study.
Tarim BA; Fici F; Tengiz I; Avunduk S; Ozcan Y; Faikoglu G; Ari E; Robles NR; Grassi G
Yonsei Med J; 2023 Mar; 64(3):175-180. PubMed ID: 36825343
[TBL] [Abstract][Full Text] [Related]
3. A Multi-Center, Open-Label, Two-Arm Parallel Group Non-inferiority Randomized Controlled Trial Evaluating the Effect of Pitavastatin, Compared to Atorvastatin, on Glucose Metabolism in Prediabetics with Hypertension and Dyslipidemia: Rationale and Design for the China Hemoglobin A1c Metabolism Protection Union Study (CAMPUS).
Zhang J; Shao Y; Liu Y; Tao J
Cardiovasc Drugs Ther; 2018 Dec; 32(6):581-589. PubMed ID: 30187345
[TBL] [Abstract][Full Text] [Related]
4. Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system.
Xiao M; Li L; Zhu W; Wu F; Wu B
Expert Rev Clin Pharmacol; 2024 Mar; 17(3):255-261. PubMed ID: 38275183
[TBL] [Abstract][Full Text] [Related]
5. The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study.
Mueller AM; Liakoni E; Schneider C; Burkard T; Jick SS; Krähenbühl S; Meier CR; Spoendlin J
J Gen Intern Med; 2021 Sep; 36(9):2639-2647. PubMed ID: 33751411
[TBL] [Abstract][Full Text] [Related]
6. Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis.
Cui JY; Zhou RR; Han S; Wang TS; Wang LQ; Xie XH
J Clin Pharm Ther; 2018 Aug; 43(4):556-570. PubMed ID: 29733433
[TBL] [Abstract][Full Text] [Related]
7. Risk of incident diabetes among patients treated with statins: population based study.
Carter AA; Gomes T; Camacho X; Juurlink DN; Shah BR; Mamdani MM
BMJ; 2013 May; 346():f2610. PubMed ID: 23704171
[TBL] [Abstract][Full Text] [Related]
8. The differences in the incidence of diabetes mellitus and prediabetes according to the type of HMG-CoA reductase inhibitors prescribed in Korean patients.
Kim TM; Kim H; Jeong YJ; Baik SJ; Yang SJ; Lee SH; Cho JH; Lee H; Yim HW; Choi IY; Yoon KH; Kim HS
Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1156-1163. PubMed ID: 28556206
[TBL] [Abstract][Full Text] [Related]
9. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Hoffman KB; Kraus C; Dimbil M; Golomb BA
PLoS One; 2012; 7(8):e42866. PubMed ID: 22936996
[TBL] [Abstract][Full Text] [Related]
10. More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
Strutt K; Caplan R; Hutchison H; Dane A; Blasetto J
Circ J; 2004 Feb; 68(2):107-13. PubMed ID: 14745143
[TBL] [Abstract][Full Text] [Related]
11. Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial.
Park JB; Jung JH; Yoon YE; Kim HL; Lee SP; Kim HK; Kim YJ; Cho GY; Sohn DW
Trials; 2017 Oct; 18(1):501. PubMed ID: 29078817
[TBL] [Abstract][Full Text] [Related]
12. Comparison of statins for primary prevention of cardiovascular disease and persistent physical disability in older adults.
Zhou Z; Curtis AJ; Ernst ME; Ryan J; Zoungas S; Wolfe R; McNeil JJ; Murray AM; Reid CM; Chowdhury EK; Woods RL; Tonkin AM; Nelson MR
Eur J Clin Pharmacol; 2022 Mar; 78(3):467-476. PubMed ID: 34698889
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Cost-Effectiveness, Safety, and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Dyslipidemic Diabetic Patients With or Without Metabolic Syndrome.
Bener A; Dogan M; Barakat L; Al-Hamaq AO
J Prim Care Community Health; 2014 Jul; 5(3):180-7. PubMed ID: 24522932
[TBL] [Abstract][Full Text] [Related]
14. Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases.
Seo WW; Seo SI; Kim Y; Yoo JJ; Shin WG; Kim J; You SC; Park RW; Park YM; Kim KJ; Rhee SY; Park M; Jin ES; Kim SE
Cardiovasc Diabetol; 2022 May; 21(1):82. PubMed ID: 35606846
[TBL] [Abstract][Full Text] [Related]
15. [Cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk in Spain].
Cosin Sales J; Fuentes Jiménez FJ; Mantilla Morató T; Ruiz E; Becerra V; Aceituno S; Ferrario MG; Lizán L; Gracia A
Clin Investig Arterioscler; 2015; 27(5):228-38. PubMed ID: 25640158
[TBL] [Abstract][Full Text] [Related]
16. Effect of Switching from Low-Dose Simvastatin to High-Dose Atorvastatin on Glucose Homeostasis and Cognitive Function in Type 2 Diabetes.
Thongtang N; Tangkittikasem N; Samaithongcharoen K; Piyapromdee J; Srinonprasert V; Sriussadaporn S
Vasc Health Risk Manag; 2020; 16():367-377. PubMed ID: 33061398
[TBL] [Abstract][Full Text] [Related]
17. Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
Cho Y; Choe E; Lee YH; Seo JW; Choi Y; Yun Y; Wang HJ; Ahn CW; Cha BS; Lee HC; Kang ES
Metabolism; 2015 Apr; 64(4):482-8. PubMed ID: 25312577
[TBL] [Abstract][Full Text] [Related]
18. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
[TBL] [Abstract][Full Text] [Related]
19. Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study.
Dave CV; Winterstein AG; Park H; Cook RL; Hartzema AG
J Affect Disord; 2018 Oct; 238():542-546. PubMed ID: 29936394
[TBL] [Abstract][Full Text] [Related]
20. Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants.
Lönnberg KI; Tornio A; Hirvensalo P; Keskitalo J; Mustaniemi AL; Kiiski JI; Filppula AM; Niemi M
Pharmacogenet Genomics; 2023 Sep; 33(7):153-160. PubMed ID: 37490620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
